Biosimilar and Interchangeable Biosimilar Conversion Programs
Drs Atheer Kaddis and Mariam Alboustani delve into biosimilar conversion programs, including switching policies for interchangeability.
Key US-Based HER2 CRC Clinical Trials
Kanwal Raghav, MD, MBBS, references several HER2 clinical trials, each presenting unique drug combinations to address metastatic colorectal cancer.
Identifying HER2 Overexpression in Patients with mCRC
Kanwal Raghav, MD, MBB, examines unmet needs in next-generation sequencing and barriers to coverage in this metastatic colorectal cancer discussion.
Economic Burden Associated with HF-Related Comorbid Disease
Panelists discuss treatment for heart failure in the presence of comorbid disease impacting payer considerations.
Aligning Value Statements and Cost-Effective Coverage In Accordance With ACC Guidelines
Ryan Haumschild, PharmD, MS, MBA, leads a conversation regarding value statements and their alignment with cost-effective care.
Automatic Substitution With Interchangeable Biosimilars
Dr Sonia T. Oskouei focuses on automatic substitution in both the pharmacy setting and in patients’ health plans.
Looking at Published Data and Implications of Interchangeability
Mariam Alboustani, PharmD, discusses the one published example of a switching study and the implications of interchangeability for pharmacists, as well as payers.
Identifying Appropriate Candidates for NGS Testing
Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC.
Emphasizing HER2 Testing as A Premier Diagnostic Approach To mCRC
Testing prioritization and frequency are highlighted in Dr Ciombor’s final insights for this HER2 biomarker focus.
Defining Interchangeable Biosimilars
Drs Kaddis and Oskouei define interchangeable biosimilars, their FDA requirements, and switching studies.
An Overview of Biosimilars and Future Agents
Atheer Kaddis, PharmD, and Sonia T. Oskouei, PharmD, BCMAS, DPLA, provide an overview of biosimilars and the preparation for future launches on the horizon.
Pillars of HF Therapy and Evidence-Based Recommendations Based on Ejection Fraction Status
Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status.
Classification of Heart Failure
A panel of medical experts open a discussion surrounding heart failure and its prevalence in health care.
Determining Appropriate mCRC Testing Strategies
Dr Ciombor provides her insight on determining appropriate testing strategies for patients with metastatic colorectal cancer.
Navigating Clinical Pathways and Improved Sequencing Awareness in mCRC
In his final thoughts, Dr Haumschild outlines opportunities for next-generation sequencing in treatment for metastatic colorectal cancer.
Payer Considerations for Molecular Testing In Metastatic Colorectal Cancer
Dr Haumschild aligns payer considerations with molecular testing and biomarker application for treatment of patients with mCRC.
The Future of NSCLC Management
Our experts conclude with their final thoughts on the future of NSCLC treatment.
Educating Payers and Providers on Advanced NSCLC With Mutations
Three medical professionals recommend educational needs for both payers and providers within the NSCLC treatment landscape.
KRAS Inhibitors in Frontline and Combination Therapy
Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies.
Exploring Advantages of Molecular Testing in CRC Treatment
Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC.
Final Thoughts on ILD
The panel concludes by offering key takeaways for viewers and listeners on ILD therapy.
Unmet Needs and New Developments in ILD Treatment
The panel participants relay unmet needs they have found when treating ILD, and discuss promising therapy developments that could improve the treatment landscape.
Resistance to KRAS G12C Inhibition
Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.
Treatment Options for KRAS-Mutated NSCLC
Alexander Spira, MD, PhD, FACP, and Joshua Sabari, MD, detail possible therapeutic options for KRAS-mutated NSCLC, focusing on adagrasib and treating brain metastases.
Evaluating Clinical Burden of Metastatic Versus Nonmetastatic CRC
Dr Kristen Ciombor explores clinical impacts during the treatment of patients with metastatic or nonmetastatic colorectal cancer.
Social Determinants Contributing to Colorectal Cancer Risk
Ryan Haumschild, PharmD, MS, MBA, reviews risk factors for colorectal cancer, including social determinants and at-risk demographics.
Educating Peers About PDTs
Our experts conclude by interpreting ways to better educate both payers and providers on PDTs.
Value-Based Pilot Programs for PDTs
Diana Brixner, RPh, PhD, comments on how incorporating value-based pilot programs would impact her decision-making with PDT coverage as a payer.
Challenges With KRAS G12C Mutations
Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments.
Overview of KRAS G12C Mutations in NSCLC
Martin Dietrich, MD, PhD, explains what KRAS G12C mutations in NSCLC are and how common they are within the NSCLC landscape.
